Immunocidin is being evaluated in the treatment of canine hemangiosarcoma by researchers at ISU College of Veterinary Medicine

NovaVive Inc.

NovaVive is a private Canadian immunobiology company founded in July, 2014. The Company acquired an advanced veterinary immunotherapeutic platform based on mycobacterium cell wall fraction (MCWF) technology with regulator-approved products for cattle, horses and dogs. These products are currently sold to veterinarians in the U.S.A., Canada, Australia and New Zealand. The Company's head office is located in Napanee, Ontario, Canada.

Sign up to stay up-to-date with NovaVive news.

Recent News

Amplimune® Administered in Calves Prior to Shipment Shows Economic Benefit

Data from a University of Minnesota research study presented by Dr. Luciano Caixeta at the AABP annual conference in St. Louis, MO last week shows an economic benefit to the use of Amplimune in calves prior to shipping.

learn more

Amplimune® Administered in Calves Prior to Shipment Demonstrates a Reduced Likelihood of Pneumonia Upon Arrival

Amplimune® given to calves prior to shipment has been shown to reduce the likelihood of pneumonia on arrival. Data from a 1,360-calf study was presented at the 2019 American Dairy Science Association Annual Meeting today.

learn more

ISU College of Veterinary Medicine to Conduct a Study with Immunocidin® in the Treatment of Canine Hemangiosarcoma

NovaVive's anticancer immunotherapeutic for dogs will be evaluated in a clinical study at Iowa State University (ISU) College of Veterinary Medicine in the treatment of splenic hemangiosarcoma (in combination with chemo).

learn more

Follow NovaVive on Social Media.